Advertisement
Screener

GSK plc (GSK) Form 6-K: Report of foreign private issuer

2.5 / 5 stars · 20/40 Roast Me

Add as a preferred source on Google

GSK plc Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2026-09-24: Form 6-K; Period of report 2026-09-24; Description DIRECTOR/PDMR SHAREHOLDING; Document a2127w.htm.
  • 2026-09-22: Form 6-K; Period of report 2026-09-22; Description DIRECTOR/PDMR SHAREHOLDING; Document a8165v.htm.
  • 2026-09-15: Form 6-K; Period of report 2026-09-15; Description GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA; Document a6888u.htm.
  • 2026-09-15: Form 6-K; Period of report 2026-09-15; Description 6-K; Document d180440d6k.htm.
FiledFormPeriod of reportDescriptionDocument
2026-09-246-K2026-09-24DIRECTOR/PDMR SHAREHOLDINGa2127w.htm
2026-09-226-K2026-09-22DIRECTOR/PDMR SHAREHOLDINGa8165v.htm
2026-09-156-K2026-09-15GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMAa6888u.htm
2026-09-156-K2026-09-156-Kd180440d6k.htm
2026-09-146-K2026-09-14RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINAa5437u.htm
2026-09-146-K2026-09-14JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLCa5235u.htm
2026-09-116-K2026-09-11DIRECTOR/PDMR SHAREHOLDINGa4618u.htm
2026-09-106-K2026-09-10DIRECTOR/PDMR SHAREHOLDINGa2959u.htm
2026-09-106-K2026-09-10JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGEa1355u.htm
2026-09-096-K2026-09-09DIRECTOR/PDMR SHAREHOLDINGa0968u.htm
2026-09-096-K2026-09-09DIRECTOR/PDMR SHAREHOLDINGa0960u.htm
2026-09-086-K2026-09-086-Kd331501d6k.htm
2026-09-016-K2026-09-01TOTAL VOTING RIGHTSa9126s.htm
2026-09-016-K2026-09-01MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE IIIa7703s.htm
2026-08-266-K2026-08-26DIRECTOR/PDMR SHAREHOLDINGa2573s.htm
2026-08-246-K2026-08-24DIRECTOR/PDMR SHAREHOLDINGa9312r.htm
2026-08-246-K2026-08-24FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPANa8443r.htm
2026-08-246-K2026-08-24US FDA TO REVIEW JEMPERLI FOR RECTAL CANCERa7607r.htm
2026-08-186-K2026-08-18DIRECTOR/PDMR SHAREHOLDINGa1253r.htm
2026-08-136-K2026-08-13DIRECTOR/PDMR SHAREHOLDINGa6279q.htm
2026-08-116-K2026-08-11DIRECTOR/PDMR SHAREHOLDINGa2463q.htm
2026-08-036-K2026-08-03TOTAL VOTING RIGHTSa9931o.htm
2026-07-306-K2026-07-30DIRECTOR/PDMR SHAREHOLDINGa5890o.htm
2026-07-286-K2026-07-28NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGEa1993o.htm
2026-07-286-K2026-07-28HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZa1904o.htm
2026-07-286-K2026-07-282ND QUARTER RESULTSa1493o.htm
2026-07-246-K2026-07-24DIRECTOR/PDMR SHAREHOLDINGa8178n.htm
2026-07-246-K2026-07-24ADMISSION TO TRADINGa8274n.htm
2026-07-226-K2026-07-22JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERSa4747n.htm
2026-07-206-K2026-07-20BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCEa9780m.htm
2026-07-176-K2026-07-17AUDIT TENDER CONCLUSIONa8186m.htm
2026-07-176-K2026-07-17CAMLIPIXANT PHASE III RESULTS UPDATEa8188m.htm
2026-07-166-K2026-07-16DIRECTOR/PDMR SHAREHOLDINGa6856m.htm
2026-07-156-K2026-07-15GSK COMPLETES ACQUISITION OF NUVALENT, INCa5060m.htm
2026-07-146-K2026-07-14DIRECTOR/PDMR SHAREHOLDINGa3283m.htm
2026-07-136-K2026-07-13DIRECTOR/PDMR SHAREHOLDINGa1372m.htm
2026-07-136-K2026-07-13POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCERa9768l.htm
2026-07-106-K2026-07-10HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZa9298l.htm
2026-07-096-K2026-07-09DIRECTOR/PDMR SHAREHOLDINGa7584l.htm
2026-07-096-K2026-07-09DIRECTORATE CHANGEa6975l.htm
2026-07-016-K2026-07-01TOTAL VOTING RIGHTSa6231k.htm
2026-06-296-K2026-06-29TRANSACTION IN OWN SHARESa2130k.htm
2026-06-296-K2026-06-29HOLDING(S) IN COMPANYa2052k.htm
2026-06-266-K2026-06-26HOLDING(S) IN COMPANYa9666j.htm
2026-06-246-K2026-06-24DIRECTOR/PDMR SHAREHOLDINGa6253j.htm
2026-06-246-K2026-06-24GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENTa6263j.htm
2026-06-236-K2026-06-23DIRECTOR/PDMR SHAREHOLDINGa3884j.htm
2026-06-226-K2026-06-22TRANSACTION IN OWN SHARESa2198j.htm
2026-06-176-K2026-06-17CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDAa7252i.htm
2026-06-156-K2026-06-15TRANSACTION IN OWN SHARESa3352i.htm
2026-06-126-K2026-06-12MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXASa0204i.htm
2026-06-116-K2026-06-11DIRECTOR/PDMR SHAREHOLDINGa9876h.htm
2026-06-106-K2026-06-10DIRECTOR/PDMR SHAREHOLDINGa7548h.htm
2026-06-096-K2026-06-09DR HAL BARRON - NEW DIRECTORSHIPa6477h.htm
2026-06-096-K2026-06-09GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC.a5507h.htm
2026-06-086-K2026-06-08TRANSACTION IN OWN SHARESa4279h.htm
2026-06-016-K2026-06-01TOTAL VOTING RIGHTSa5105g.htm
2026-06-016-K2026-06-01TRANSACTION IN OWN SHARESa4680g.htm
2026-05-286-K2026-05-28POSITIVE PHASE 3 DATA FOR BEPIROVIRSENa0471g.htm
2026-05-276-K2026-05-27DIRECTOR/PDMR SHAREHOLDINGa9163f.htm
2026-05-266-K2026-05-26ADMISSION TO TRADINGa7508f.htm
2026-05-266-K2026-05-26TRANSACTION IN OWN SHARESa7372f.htm
2026-05-226-K2026-05-22Q2 2026 RESULTS DATE CONFIRMED - 28 JULY 2026a4774f.htm
2026-05-206-K2026-05-20DIRECTOR/PDMR SHAREHOLDINGa1412f.htm
2026-05-206-K2026-05-20DIRECTOR/PDMR SHAREHOLDINGa1412f.htm
2026-05-196-K2026-05-19DIRECTOR/PDMR SHAREHOLDINGa9634e.htm
2026-05-186-K2026-05-18TRANSACTION IN OWN SHARESa7748e.htm
2026-05-186-K2026-05-18JAPAN MHLW APPROVES AREXVY FOR ADULTS 18-49 AIRa5853e.htm
2026-05-146-K2026-05-14DIRECTOR/PDMR SHAREHOLDINGa3914e.htm
2026-05-116-K2026-05-11DIRECTOR/PDMR SHAREHOLDINGa8085d.htm
2026-05-116-K2026-05-11COLLABORATION WITH CTTQ FOR BEPIROVIRSENa7648d.htm
2026-05-116-K2026-05-11GSK - FINAL TRANCHE OF SHARE BUYBACK PROGRAMMEa6811d.htm
2026-05-066-K2026-05-06RESULT OF AGMa3151d.htm
2026-05-056-K2026-05-05DIRECTOR/PDMR SHAREHOLDINGa0891d.htm
2026-05-016-K2026-05-01TOTAL VOTING RIGHTSa8497c.htm
2026-05-016-K2026-05-01HOLDING(S) IN COMPANYa8483c.htm
2026-04-296-K2026-04-29DIRECTOR/PDMR SHAREHOLDINGa4424c.htm
2026-04-296-K2026-04-291ST QUARTER RESULTSa2755c.htm
2026-04-286-K2026-04-28DIRECTOR/PDMR SHAREHOLDINGa2567c.htm
2026-04-286-K2026-04-28BEPIROVIRSEN PRIORITY REVIEW US FILING ACCEPTANCEa1144c.htm
2026-04-276-K2026-04-27EFIMOSFERMIN GRANTED US/EU REGULATORY DESIGNATIONSa0447c.htm
2026-04-276-K2026-04-27TESARO UPDATE ON ANAPTYSBIO INC. LITIGATIONa9967b.htm
2026-04-246-K2026-04-24DIRECTOR/PDMR SHAREHOLDINGa8882b.htm
2026-04-236-K2026-04-23TRANSACTION IN OWN SHARESa5557b.htm
2026-04-226-K2026-04-22TRANSACTION IN OWN SHARESa3762b.htm
2026-04-216-K2026-04-21TRANSACTION IN OWN SHARESa1995b.htm
2026-04-206-K2026-04-20DIRECTOR/PDMR SHAREHOLDINGa1813b.htm
2026-04-206-K2026-04-20BLENREP APPROVED IN CHINA FOR 2L+ MULTIPLE MYELOMAa0194b.htm
2026-04-206-K2026-04-20TRANSACTION IN OWN SHARESa0050b.htm
2026-04-176-K2026-04-17TRANSACTION IN OWN SHARESa8309a.htm
2026-04-166-K2026-04-16DIRECTOR/PDMR SHAREHOLDINGa8099a.htm
2026-04-166-K2026-04-16TRANSACTION IN OWN SHARESa6492a.htm
2026-04-156-K2026-04-15GSK COMPLETES ACQUISITION OF 35PHARMA INC.a5562a.htm
2026-04-156-K2026-04-15TRANSACTION IN OWN SHARESa4784a.htm
2026-04-146-K2026-04-14DIRECTOR/PDMR SHAREHOLDINGa4478a.htm
2026-04-146-K2026-04-14TRANSACTION IN OWN SHARESa2720a.htm
2026-04-136-K2026-04-13DIRECTOR/PDMR SHAREHOLDINGa2553a.htm
2026-04-136-K2026-04-13GSK PRESENTS POSITIVE DATA FOR BEHOLD 1 B7 H4 ADCa0706a.htm
2026-04-136-K2026-04-13TRANSACTION IN OWN SHARESa0718a.htm
2026-04-106-K2026-04-10DIRECTOR/PDMR SHAREHOLDINGa0489a.htm
Advertisement